Deutsche Bank AG acquired a new position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 132,705 shares of the company's stock, valued at approximately $11,986,000. Deutsche Bank AG owned about 0.16% of HealthEquity as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of HQY. Fifth Third Wealth Advisors LLC raised its position in HealthEquity by 4.2% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,872 shares of the company's stock valued at $240,000 after buying an additional 116 shares during the last quarter. Truist Financial Corp grew its stake in shares of HealthEquity by 4.9% in the 4th quarter. Truist Financial Corp now owns 2,537 shares of the company's stock worth $232,000 after acquiring an additional 119 shares in the last quarter. Fiduciary Trust Co raised its holdings in shares of HealthEquity by 3.4% in the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company's stock valued at $348,000 after purchasing an additional 120 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of HealthEquity by 24.4% in the third quarter. Larson Financial Group LLC now owns 628 shares of the company's stock valued at $60,000 after purchasing an additional 123 shares during the last quarter. Finally, Merit Financial Group LLC lifted its position in shares of HealthEquity by 8.9% during the third quarter. Merit Financial Group LLC now owns 2,112 shares of the company's stock valued at $200,000 after purchasing an additional 172 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.
HealthEquity Trading Up 1.1%
Shares of HQY stock opened at $105.41 on Friday. The company has a 50 day moving average of $96.64 and a 200-day moving average of $87.20. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The firm has a market cap of $8.81 billion, a P/E ratio of 39.48, a PEG ratio of 1.77 and a beta of 0.21.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million for the quarter, compared to analysts' expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts anticipate that HealthEquity, Inc. will post 3.92 earnings per share for the current year.
Insider Transactions at HealthEquity
In related news, EVP Michael Henry Fiore sold 3,142 shares of HealthEquity stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $95.00, for a total value of $298,490.00. Following the completion of the sale, the executive vice president owned 59,113 shares of the company's stock, valued at approximately $5,615,735. This trade represents a 5.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the business's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. Following the sale, the executive vice president directly owned 91,141 shares in the company, valued at $8,202,690. The trade was a 7.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 17,905 shares of company stock worth $1,651,280. 1.60% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on HQY. KeyCorp reaffirmed an "overweight" rating on shares of HealthEquity in a research report on Tuesday, May 26th. Barrington Research restated an "outperform" rating and issued a $110.00 target price on shares of HealthEquity in a research note on Friday, May 22nd. Wall Street Zen raised HealthEquity from a "hold" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company set a $111.00 price target on HealthEquity in a research report on Monday, June 1st. Finally, Weiss Ratings raised HealthEquity from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, June 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $110.93.
View Our Latest Analysis on HQY
About HealthEquity
(
Free Report)
HealthEquity, Inc NASDAQ: HQY is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
